Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Cricopharyngeal Achalasia
Interventions
DRUG

Injectable Type A Botulinum Toxin

Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.

Trial Locations (1)

Unknown

RECRUITING

Xinzhu Rehabilitation Hospital, Xinzhu

All Listed Sponsors
lead

Zeng Changhao

OTHER